BioMarin Pharmaceutical Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über BioMarin Pharmaceutical Inc Unternehmen

BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.

BioMarin Pharmaceutical Inc Informationen



BörsenkürzelBMRN

Name des UnternehmensBioMarin Pharmaceutical Inc

IPO-datumJul 23, 1999

CEOHardy (Alexander)

Anzahl der mitarbeiter3040

WertpapierartOrdinary Share

GeschäftsjahresendeJul 23

Addresse770 Lindaro Street

StadtSAN RAFAEL

BörseNASDAQ OMX - NASDAQ BASIC

LandUnited States of America

Postleitzahl94901

Telefon14155066700

Websitehttps://www.biomarin.com/

BörsenkürzelBMRN

IPO-datumJul 23, 1999

CEOHardy (Alexander)

Führungskräfte von BioMarin Pharmaceutical Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Richard A. (Randy) Meier

Non-Executive Independent Chairman of the Board

120.34K

+6650.00%

Mr. Alexander Hardy

President, Chief Executive Officer, Director

46.80K

-16570.00%

Dr. Gregory R Friberg, M.D.

Executive Vice President, Chief Research & Development Officer

43.51K

-3304.00%

Mr. Robert J. (Bob) Hombach, CPA

Independent Director

37.15K

+6650.00%

Ms. Cristin Hubbard

Executive Vice President, Chief Commercial Officer

30.55K

-2428.00%

Dr. Maykin Ho, Ph.D.

Independent Director

23.29K

+6650.00%

Ms. Barbara W. Bodem

Independent Director

8.83K

+6650.00%

Dr. Athena M. Countouriotis, M.D.

Independent Director

8.83K

+6650.00%

Mr. G. Eric Davis

Executive Vice President, Secretary, Chief Legal Officer

--

Mr. Brian R. Mueller, CPA

Chief Financial Officer, Executive Vice President, Principal Accounting Officer

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Richard A. (Randy) Meier

Non-Executive Independent Chairman of the Board

120.34K

+6650.00%

Mr. Alexander Hardy

President, Chief Executive Officer, Director

46.80K

-16570.00%

Dr. Gregory R Friberg, M.D.

Executive Vice President, Chief Research & Development Officer

43.51K

-3304.00%

Mr. Robert J. (Bob) Hombach, CPA

Independent Director

37.15K

+6650.00%

Ms. Cristin Hubbard

Executive Vice President, Chief Commercial Officer

30.55K

-2428.00%

Dr. Maykin Ho, Ph.D.

Independent Director

23.29K

+6650.00%

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Voxzogo

218.39M

28.70%

Vimizim

182.75M

24.02%

Naglazyme

122.03M

16.04%

Palynziq

108.78M

14.30%

Aldurazyme

53.71M

7.06%

Andere

75.16M

9.88%

Nach RegionUSD

Name

Umsatz

Anteil

United States

274.11M

36.03%

Europe

195.18M

25.65%

Rest of the world

140.19M

18.43%

Latin America

97.62M

12.83%

ALDURAZYME net product revenues marked by Sanofi

53.71M

7.06%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Voxzogo

218.39M

28.70%

Vimizim

182.75M

24.02%

Naglazyme

122.03M

16.04%

Palynziq

108.78M

14.30%

Aldurazyme

53.71M

7.06%

Andere

75.16M

9.88%

Aktionärsstatistik

Aktualisiert: Fri, Feb 6

Aktionäre

Aktionärstypen

Aktionäre

Anteil

The Vanguard Group, Inc.

9.41%

BlackRock Institutional Trust Company, N.A.

8.98%

PRIMECAP Management Company

7.93%

Dodge & Cox

7.64%

State Street Investment Management (US)

4.56%

Andere

61.48%

Aktionäre

Anteil

The Vanguard Group, Inc.

9.41%

BlackRock Institutional Trust Company, N.A.

8.98%

PRIMECAP Management Company

7.93%

Dodge & Cox

7.64%

State Street Investment Management (US)

4.56%

Andere

61.48%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

46.60%

Investment Advisor/Hedge Fund

37.53%

Hedge Fund

6.69%

Pension Fund

3.03%

Sovereign Wealth Fund

1.40%

Research Firm

1.35%

Individual Investor

0.74%

Bank and Trust

0.67%

Venture Capital

0.35%

Andere

1.64%

Institutionelle Beteiligung



Aktualisiert: Mon, Dec 8

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

1296

187.90M

108.82%

+71.66K

2025Q3

1334

187.86M

111.13%

-2.15M

2025Q2

1344

190.17M

114.04%

-8.63M

2025Q1

1331

198.83M

113.78%

-19.35M

2024Q4

1317

196.49M

110.91%

+4.70M

2024Q3

1283

191.71M

111.61%

-4.43M

2024Q2

1271

195.66M

108.22%

+2.33M

2024Q1

1257

193.46M

109.63%

-14.58M

2023Q4

1275

195.75M

103.93%

+7.49M

2023Q3

1255

188.56M

102.57%

+2.75M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

The Vanguard Group, Inc.

18.49M

9.63%

-419.17K

-2.22%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

17.25M

8.98%

-790.94K

-4.38%

Sep 30, 2025

PRIMECAP Management Company

15.23M

7.93%

-542.89K

-3.44%

Sep 30, 2025

Dodge & Cox

14.69M

7.64%

-421.51K

-2.79%

Sep 30, 2025

State Street Investment Management (US)

8.76M

4.56%

-83.15K

-0.94%

Sep 30, 2025

Viking Global Investors LP

8.32M

4.33%

-3.97M

-32.28%

Sep 30, 2025

AQR Capital Management, LLC

5.93M

3.09%

+351.54K

+6.30%

Sep 30, 2025

Geode Capital Management, L.L.C.

3.54M

1.84%

+67.68K

+1.95%

Sep 30, 2025

Rothschild & Co Asset Management Europe SCS

2.63M

1.37%

+317.58K

+13.74%

Nov 30, 2025

Millennium Management LLC

2.63M

1.37%

-207.15K

-7.31%

Sep 30, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

First Trust NYSE Arca Biotechnology Index Fund

3.44%

Global X Genomics & Biotechnology ETF

2.98%

Invesco Biotechnology & Genome ETF

2.47%

First Trust Health Care Alphadex Fund

2.15%

Goldman Sachs Future Health Care Equity ETF

2.15%

State Street SPDR S&P Biotech ETF

1.93%

WealthTrust DBS Long Term Growth ETF

1.86%

Alger Russell Innovation ETF

1.84%

Virtus LifeSci Biotech Products ETF

1.5%

VanEck Biotech ETF

1.4%

First Trust NYSE Arca Biotechnology Index Fund

Anteil3.44%

Global X Genomics & Biotechnology ETF

Anteil2.98%

Invesco Biotechnology & Genome ETF

Anteil2.47%

First Trust Health Care Alphadex Fund

Anteil2.15%

Goldman Sachs Future Health Care Equity ETF

Anteil2.15%

State Street SPDR S&P Biotech ETF

Anteil1.93%

WealthTrust DBS Long Term Growth ETF

Anteil1.86%

Alger Russell Innovation ETF

Anteil1.84%

Virtus LifeSci Biotech Products ETF

Anteil1.5%

VanEck Biotech ETF

Anteil1.4%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten